News

Prof. Dr. Kees Hovingh joins Julius Clinical as Scientific Officer

Julius Clinical is pleased to announce that Prof. Kees Hovingh has joined Julius Clinical as Scientific Officer, specialising in Cardiovascular disease, with a sub-speciality in Internal medicine, molecular genetics and atherosclerosis.

read more

Real-World Evidence in Medicine Development: an online introductory course

Following the success of the earlier editions of the course, we are pleased to announce that enrollment for the third edition is now open. The course will run from September 3 – October 26, 2018. Click here for more information and enrollment.

read more

EU H2020 grant for unique HIT-Cystic Fibrosis project

The EU has granted 6.7 M€ from the Horizon 2020 research program to a broad collaborative group of researchers, doctors, pharmaceutical companies and patient representatives. Julius Clinical is one of the consortium partners and will be responsible for global Site Management, Monitoring, Data Management and Safety Management for the clinical part of the project. For more details, please click here

read more

Julius Clinical appoints new Chief Commercial Officer

Former PRA executive, Arnoud Huisman, appointed as CCO

Zeist, 1 June 2018 - Julius Clinical’s Board of Directors is pleased to announce that Arnoud Huisman will join the company as its new Chief Commercial Officer. Mr. Huisman succeeds Andrew Copestake, who left the company to pursue other interests earlier this year.

read more

Meet us at AAIC in Chicago

If you are interested in finding out how we can help you run a cost-effective and creative trial, send us an email. We look forward to seeing you at the AAIC in July.

AAIC, Chicago, IL. 22-25 July

read more

Official Launch of the ReSViNET Foundation

Today, we proudly announce the official launch of the ReSViNET Foundation as a registered not-for-profit entity under Dutch law. After four years of building and shaping the network, and months of preparation, the ReSViNET Foundation has officially been founded. 

As a foundation ReSViNET is now a financially and otherwise independent regulated entity which represents a major milestone for the entire ReSViNET project. Since the inception of ReSViNET network in 2014, we have continuously been working to fulfil our Vision and Mission: to decrease the global burden of RSV infection through the advancement of research; providing scientific input; involvement in clinical trials; and organising conferences and offering platforms to share the latest developments and  reports on groundbreaking studies and in this way helping to move the field forward.

read more

Why have RWE trials become "the thing to do"?

Real world data has been around for a very long time, but its significance has not been well understood, and therefore, the potential for improving health care has not been fully utilized.

read more

Netherlands General Practioner Event 2018

On Saturday 7 April, the National General Practioner Association in The Netherlands held their annual General Practioner Event in the Jaarbeurs in Utrecht, The Netherlands with the theme Ambition.

The objective of the event was to inspire, educate and share information in a positive and energetic way.

At the event, the Association shared the most recent developments in the area of primary care closer to the members. The GP event is a unique, one day event where knowledge, expertise, experience products and services in primary care are shared. The old-fashioned printed event catalogue was replaced by an app that was used by more than 1600 visitors.

All in all, there were more than 3500 visitors to the event, mainly from primary care practices, for a day filled with information, training and inspiration. Julius Clinical was also present with a brand new stand. The Primary Care Liaisons (PCL) Nathalie Groetelaers, Aline Veurink-Westrik and Ellen Ijlstra represented Julius Clinical, and there was much attention given to our new studies on COPD and MACH15 (the alcohol study). Visitors to our stand had good questions about the studies, and from this we were able to register more Primary Care Research Network (PCRN) participants. We also welcomed current members of PCRN to our stand, and it was nice to see familiar faces, such as Dr. Alfred Sachs, Primary Investigator for the COPD study. Many GPs recognised him and that led to several interesting discussions between him and the PCLs about the study.

It was a dynamic and positive event, wherein clinical research was in the spotlight and Julius Clinical’s name recognition improved greatly.

 

read more

Real World Evidence – an introduction

Everybody is talking about real world evidence (RWE) these days, but what is it exactly?

There is an abundance of articles on this topic that have, no doubt, been read by many people. This article aims to explain it in terms our Grandmothers could understand and is the first in a series of articles on RWE.

read more

ClinOPS Day 2018 was an inspiring event

Julius Clinical was present at the 8th ClinOPS day in Veenendaal on 12 April.

It was a successful day with inspiring plenary sessions that aimed to bring out the best of each clinical professional that attended the sessions, motivating them to look at clinical research from a different viewpoint. It was good to step out of the daily routine and learn new things, and where one of the messages is certainly a trigger for reflection: doing is the better thinking.  

read more

Julius Clinical to coordinate worldwide study on the effects of alcohol

The health effects of moderate (no more than 2 alcoholic beverages each day) alcohol consumption is still debated. Many studies have found that adults who reported drinking alcohol in moderation tended to develop heart disease and diabetes less often than adults who drank no alcohol. However, other studies found opposite results or showed no relationship between alcohol intake and these diseases. This study hopes to definitively answer this question.

read more

A successful and valuable RSV Vaccines for the World Conference

The annual RSV Vaccines for the World Conference was held this year in Malaga Spain, from Nov 29th to Dec 1st. The conference was organised by ReSViNET, the RSV network managed and operated by Julius Clinical and the University Medical Center Utrecht.

read more

Jennifer Hart joins Julius Clinical

We are pleased to announce that Jennifer Hart has joined our company as Executive Director Business Development North America. In her new role as Executive Director, Ms. Hart will oversee the North American Business Development efforts for Julius Clinical and Cohortias, a joint venture between Julius Clinical and Zumanis. 

read more

Amsterdam is the new home for the European Medicines Agency

Amsterdam has succeeded in its bid to host the European Medicines Agency (EMA) when the organisation leaves London following Brexit.

read more

Julius Clinical Forms Alliance With Parexel

Alliance aims to strengthen global clinical trial services by aligning scientific and operational aspects of clinical trials

Utrecht, Netherlands, January 25, 2017 — Julius Clinical, a globally-operating Academic Research Organization (ARO), today announced it has entered into a non-exclusive alliance with PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organisation. The alliance provides biopharmaceutical companies an approach to aligning scientific and operational aspects of a clinical trial.

read more